Is Eden Health right for you?
Eden (legal name: Eden Health International Inc.) is a U.S. digital‑health platform focused on metabolic health and related wellness therapies. Through Eden you complete an online intake, meet a state‑licensed provider via telehealth, and receive medications by mail from Eden Pharmacy or a partner pharmacy. The site markets “same price at every dose,” free expedited shipping, and cancellation‑friendly monthly plans.
Eden is not the same organization as the employer‑focused primary‑care company at edenhealth.com. This review covers Eden at tryeden.com and its integrated Eden Pharmacy offering.
Recent development: in‑house compounding
On Aug 19, 2025, Eden announced it acquired Contigo Compounding (a licensed 503A compounding pharmacy) and rebranded it Eden Pharmacy. The press release touts USP <797>/<800> compliance and “free next‑day shipping,” while Eden’s pharmacy page says “Contigo is now Eden Pharmacy!” and notes current licensure in eight states (with partner pharmacies elsewhere). This vertical integration can reduce handoffs and order delays but also places higher expectations on Eden’s quality controls.
How Eden works (at a glance)
Eden lays out a four‑step process: a 3‑minute questionnaire, a telehealth consult, medication if eligible, and ongoing care. Several program pages emphasize free expedited shipping, “same‑day doctor visits,” and 24/7 messaging once you’re enrolled. Support hours for non‑clinical customer care are Mon–Fri, 10am–6pm ET.
Medication options & scope of services
Eden markets access to FDA‑approved GLP‑1 brands: Ozempic®, Wegovy®, Zepbound®, Mounjaro® as well as compounded GLP‑1s (not FDA‑approved) and oral “kit” components (e.g., metformin, bupropion, topiramate, naltrexone, vitamin B12) when clinically appropriate. Eden also lists NAD+, glutathione, methylene blue, sermorelin, and hair‑loss and hormone‑support treatments across its catalog. Availability and pricing vary by plan and state.
Regulatory context you should know: The FDA declared the semaglutide shortage resolved on Feb 21, 2025 and previously declared the tirzepatide shortage resolved on Oct 2, 2024. When a shortage is resolved, federal law sharply limits compounding of “essentially a copy” of the brand‑name drug. The FDA has also published multiple safety communications about unapproved compounded GLP‑1s, dosing errors, and counterfeit risks. Eden’s own content acknowledges these changes, noting compounded tirzepatide is no longer allowed nationwide, and that compounding policies hinge on drug‑shortage status. If you’re considering a compounded option, weigh benefits against these risks and constraints.

